© 1996 British Society for Rheumatology
other |
FURTHER CHARACTERIZATION OF ANTI-ENDOTHELIAL CELL ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS BY CONTROLLED IMMUNOBLOTTING
University Departments of Medicine Northern General Hospital Sheffield
*Unversity Departments of Immunology, Northern General Hospital Sheffield
Department of Medicine and Therapeutics University of Aberdeen
Correspondence to:
Correspondence to: P. Hughes, Department of Medicine, Clinical Sciences Centre, Northern General Hospital, Sheffield S5 7AU
Anti-endothelial cell antibodies in systemic lupus erythematosus were further characterized by controlled immunoblotting studies with EN4 defined membrane and cytosol preparations of human umbilical vein endothelial cells. Antibodies to endothelial cell membranes, some of which reacted with the membranes of both dermal fibroblasts and T-cell lymphoma HUT78, were detected in 26/33 patients (78%), but in only 4/34 normal controls (P < 0.001) and 3/11 patients with a recent myocardial infarction. Although the antibody response was very heterogeneous against epitopes ranging from 17 to 205 leDa, there was a tendency to detect particular membrane epitopes at 31–33 kDa (15 cases), 72–78 kDa (eight cases), 66–68 kDa (seven cases) and 17–19 kDa (five cases). No correlations between antibodies to particular epitopes and disease manifestations were observed nor was a relationship to disease activity detected in a retrospective analysis. However, the possibility that anti-endothelial cell antibodies may be pathogcnically important was supported by prospective serial studies in two cases with nephritis who showed diminution and disappearance of anti-endothelial cell antibodies as their active disease was treated into remission.
KEY WORDS: Endothelial membranes, Anti-endothelial cell antibodies, Systemic lupus erythematosus
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Domiciano, J. Carvalho, and Y. Shoenfeld Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases Lupus, November 1, 2009; 18(13): 1233 - 1238. [Abstract] [PDF]
|
|
|
|
 |
|
 C Belizna, A Duijvestijn, M Hamidou, and J W Cohen Tervaert Antiendothelial cell antibodies in vasculitis and connective tissue disease Ann Rheum Dis, December 1, 2006; 65(12): 1545 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Yazici, E. Raschi, A. Patel, C. Testoni, M.O. Borghi, A. M. Graham, P. L. Meroni, and N. Lindsey Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro Int. Immunol., March 1, 2001; 13(3): 349 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N D. Papa, E Raschi, G Moroni, P Panzeri, M O Borghi, C Ponticelli, A Tincani, G Balestrieri, and P L Meroni Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-infiammatory phenotype in vitro Lupus, July 1, 1999; 8(6): 423 - 429. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Frostegard, R. Wu, C. Gillis-Haegerstrand, C. Lemne, and U. de Faire Antibodies to Endothelial Cells in Borderline Hypertension Circulation, September 15, 1998; 98(11): 1092 - 1098. [Abstract] [Full Text] [PDF]
|
|